- Sens. Sherrod Brown and Bernie Sanders send letter to USTR condemning pressure on Colombia compulsory license for cancer drug
- 15 House Dems Press USTR to Clarify Position on Compulsory Licensing of cancer drug patent in Colombia
- Senator Hatch Defends Pressure on Colombia in Interview Regarding Imatinib
- WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies
- Letter from KEI, Public Citizen, Oxfam America and Health GAP to Senator Hatch, regarding Colombia Compulsory License
- 13 non-profits urge Senate HELP Committee to block floor amendments to 21st Century Cures Act counterpart
- 122 experts defend Colombia's right to issue compulsory license on imatinib in face of U.S. pressure
- SCCR32 Day 4 Strong statement on education by the American University PIJIP
- April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents
- SCCR 32 KEI on Orphan Works
The dearth of recent compulsory licenses out of India has led to speculation that the Government has made an agreement not to issue such licenses.
On reviewing submissions for the Office of the United States Trade Representative's upcoming 2016 Special 301 Review, several industry documents confirm that such an agreement exists.
KEI is one of the non-government entities speaking at the USTR Special 301 hearing on Tuesday. We each get 7 minutes of testimony and 3 minutes of questions. (The schedule is here).
KEI intervention: TTIP Stakeholder events Round 12, Brussels (24 February 2016)
A Positive Agenda for TTIP - What we would like to see in the TTIP that would expand access to knowledge?
1) Marrakesh Treaty ratification
The TTIP should include an obligation to ratify and to implement the WIPO Marrakesh Treaty for Persons Who Are Blind for Otherwise Disabled, in order to expand access to accessible works to persons with disabilities in the European Union and the United States, as well as in other countries.
2016: KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents to AltraTechSubmitted by KEI Staff on 23. February 2016 - 1:30
Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses
February 22, 2016
Patrick McCue, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
The National Institutes of Diabetes and Digestive and Kidney Diseases
12A South Drive
Bethesda, MD 20892
via email: email@example.com
Dear Dr. McCue:
I am in a meeting of the Equitable Access Initiative (EAI), which is considering new ways of measuring development and/or health needs, in the context of the priority setting by donors. I am a member of the Expert Panel, and this was my intervention in the morning session:
The presentations by John McArthur and Dominik Zotti were excellent, and the work of the four expert groups is a very useful contribution for those struggling with the challenge of setting priorities for aid.
5 questions about NIH licenses to patents on Production of Attenuated Respiratory Syncytial Virus VaccinesSubmitted by James Love on 22. February 2016 - 0:59
The NIH has a notice for comments on proposed licenses of several patents relating to the "Production of Attenuated Respiratory Syncytial Virus Vaccines". See: https://federalregister.gov/a/2016-03486
We asked Peter Soukas, a Senior Technology Licensing Specialist in the Technology Transfer and Intellectual Property Office, at the National Institute of Allergy and Infectious Diseases (NIAID), these questions:
- What provisions exist in the license to protect US residents against excessive or unreasonable pricing?
Submission of Knowledge Ecology International
U.S. Copyright Office Docket No. 2015-6
This is the submission of Knowledge Ecology International (KEI) in response to the U.S. Copyright Office request for public comment on “software-enabled consumer products” (U.S. Copyright Office Docket No. 2015-6).
Knowledge Ecology International is a non-governmental organization with offices in Washington, DC, and Geneva, Switzerland, that searches for better outcomes, including new solutions, to the management of knowledge resources.
This submission covers these topics:
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Limit ExportsSubmitted by Claire Cassedy on 12. February 2016 - 14:35
CONTACT: Zack Struver
+1 (202) 332-2670
Obama Administration Recommends Senate Ratify Marrakesh Treaty for the Blind; Implementation Language Would Seriously Limit Exports
WTO TRIPS Council (March 2016) to discuss Intellectual Property and Innovation: Education and DiffusionSubmitted by thiru on 12. February 2016 - 12:47
The World Trade Organization (WTO) will convene its Council for TRIPS (TRIPS Council) from Tuesday, 1 March 2016 to Wednesday, 2 March 2016. Australia, the European Union, Switzerland and the United States of America have submitted a written request for the item "Intellectual Property and Innovation: Education and Diffusion" to be placed on the proposed agenda.
5 FEBRUARY 2016
SUBJECT: COUNCIL FOR TRIPS
THE NEXT MEETING OF THE COUNCIL FOR TRIPS WILL BE HELD IN THE CENTRE WILLIAM RAPPARD ON 1-2 MARCH 2016. THE MEETING WILL START AT
This is the announcement.
For Immediate Release February 10, 2016
TO THE SENATE OF THE UNITED STATES:
With a view to receiving the advice and consent of the Senate to ratification, I transmit herewith the Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired, or Otherwise Print Disabled, done at Marrakesh on June 27, 2013 (Marrakesh Treaty). I also transmit, for the information of the Senate, a report of the Secretary of State with respect to the Marrakesh Treaty that includes a summary of its provisions.
USPTO White Paper Suggests Statutory Factors To Clarify Extent of Statutory Damages for Copyright InfringementSubmitted by Salvatore Angotti on 10. February 2016 - 14:13
By Salvatore Angotti*
On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.
In May 2014, the 67th World Health Assembly (WHA) of the World Health Organization (WHO) passed Decision WHA67(15) providing WHO the mandate to explore the feasibility of creating a voluntary pooled fund fund on R&D hosted by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The Decision outlined three principles guiding the consideration of the pooled fund:
Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage
Knowledge Ecology International
26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal "march-in" rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.